| Objective To compare and analyze the clinical efficacy and safety of sacubitril valsartan and enalapril in the treatment of patients with heart failure with reduced ejection fraction(HFr EF).Methods 100 patients with HFr EF who were treated in the First Affiliated Hospital of Jiamusi University from June 2018 to June 2019 were selected.After admission,the patients were randomly divided into 50 groups: the experimental group and the control group.Patients in both groups were given conventional treatment(β-blockers,diuretics,vasodilators)after admission.The test group was given sacubitril valsartan sodium on the basis of conventional treatment,and the control group was given enalapril on the same basic treatment as the test group.Record the basic information of 100 patients at the time of admission,including gender,age,previous medical history,and previous medication,and measure the serum N-terminal probrain natriuretic peptide(NT-pro BNP)of all patients.Left ventricular ejection fraction(LVEF),left ventricular end-diastolic diamete(LVEDD),6-minute walk test(6MWT)distance and other related indicators.The cardiac function of patients admitted was classified according to the New York Heart Association(NYHA)cardiac function grading standard.Follow-up NT-pro BNP,LVEF,LVEDD,6MWT distance,and cardiac function classification at 1 month,3 months,and6 months of treatment in two groups of patients and evaluate the efficacy of the treatment.The above-mentioned indicators of the two groups of patients were compared within and between groups,and the changes of the indicators before and after treatment in the two groups of patients were analyzed and compared,and the changes of the indicators between the two groups were analyzed.After 6 months of treatment,the drug safety analysis was performed based on the presence or absence of side effects.Results There was no significant difference in the basic information and indicators between the two groups of patients at admission(P>0.05).At 1 month of treatment,the significant difference was observed in LVEF and LVEDD between the two groups compared with the same group before treatment(P>0.05),and there was no significant difference between the two groups(P>0.05);NT-pro BNP,6MWT distance in the two groups was statistically significant compared with the same group before treatment(P<0.05),and the difference between the two groups was not statistically significant(P>0.05).There was no significant distinction in the effective rate of treatment between the experimental group and the control group(P>0.05).At 3 months of treatment,the follow-up of LVEF and LVEDD between the two groups was statistically significant(P<0.05),and there was no significant disparity between the two groups(P>0.05).NT-pro BNP,6MWT distance was statistically significant in comparison with the same group before treatment(P<0.05),and the difference between the two groups was statistically significant(P<0.05);the effective rate of treatment in the experimental group was not significantly different than that in the control group(P>0.05).At 6 months of treatment,the follow-up of LVEF,LVEDD,NT-pro BNP,and 6MWT distance between the two groups was statistically significant compared with that of the same group before treatment(P<0.05),and the distinction between the two groups was statistically significant(P<0.05);In comparison with the control group,the effective rate of treatment in the experimental group was significantly different(P<0.05).There were no significant differences in overall adverse reactions and adverse clinical events between the experimental and control groups(P>0.05).Conclusions In contrast to enalapril,sacubitril valsartan can further reduce NT-pro BNP,increase LVEF,reduce LVEDD,improve heart function,and increase activity tolerance in patients with HFr EF,with the extension of the treatment course,the treatment effect is more prominent. |
PDF Full Text Request